Cosopt (dorzolamide, timolol) eye drops solution 5 ml.

$27.90

Manufacturer: Singapore

Purpose: Reduces intraocular pressure by decreasing fluid production in glaucoma treatment.

SKU: MED57498 Category:

Description

Cosopt Eye Drops Solution

Composition

Active ingredients: Dorzolamide hydrochloride and Timolol maleate.

Inactive ingredients: Mannitol, carbomer 974P, tyloxapol, edetate disodium, sodium chloride, purified water, and benzalkonium chloride.

Mechanism of Action

Cosopt combines dorzolamide and timolol to reduce intraocular pressure. Dorzolamide inhibits carbonic anhydrase, decreasing aqueous humor production, while timolol, a beta-adrenergic antagonist, reduces aqueous humor formation.

Pharmacological Properties

Cosopt effectively lowers intraocular pressure by dual mechanisms of action, offering a greater reduction compared to monotherapy.

Indications for Use

Cosopt is indicated for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Contraindications

Avoid Cosopt if allergic to any ingredient, have asthma, severe COPD, bradycardia, heart block, or certain medications.

Side Effects

Possible side effects include blurred vision, eye irritation, and stinging upon administration. Regular monitoring is essential.

Usage Instructions

Shake well before use. Instill one drop into the affected eye(s) twice daily. Avoid dropper tip contact with eyes to prevent contamination.

Benefits Compared to Analogues

Cosopt’s combination therapy offers superior intraocular pressure reduction compared to monotherapy, enhancing patient compliance.

Suitable Patient Groups

Cosopt is suitable for adults and elderly patients with open-angle glaucoma or ocular hypertension.

Storage and Shelf Life

Store Cosopt at room temperature away from light and moisture. Discard after the expiration date printed on the packaging.

Packaging Description

Cosopt is available in a 5 ml eye drops solution container.

Clinical Evidence and Effectiveness

Pharmacological studies support Cosopt’s efficacy in managing intraocular pressure. Xiong et al. (2019) demonstrated the superior efficacy of dorzolamide-timolol combination therapy over timolol monotherapy in reducing intraocular pressure.